Ablative Solutions Overview
- Year Founded
-
2011
- Status
-
Private
- Employees
-
19
- Latest Deal Type
-
Series 2
- Latest Deal Amount
-
$76.9M
- Investors
-
11
Ablative Solutions General Information
Description
Developer of catheter-based neurolytic delivery systems designed for therapeutic intervention in hypertension. The company's platform incorporates a proprietary infusion catheter equipped with guided microneedles that deliver neurolytic agents into the perivascular space surrounding renal arteries, enabling healthcare providers to perform targeted renal denervation procedures with fluoroscopic guidance, minimal invasiveness, and enhanced anatomical precision to address treatment-resistant high blood pressure.
Contact Information
Website
www.ablativesolutions.comCorporate Office
- 301 Edgewater Place
- Suite 100
- Wakefield, MA 01880
- United States
Corporate Office
- 301 Edgewater Place
- Suite 100
- Wakefield, MA 01880
- United States
Ablative Solutions Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Later Stage VC (Series 2) | 26-Nov-2025 | $76.9M | Completed | Generating Revenue | ||
| 6. Later Stage VC (Series D2) | 13-Jun-2022 | Completed | Clinical Trials - General | |||
| 5. Secondary Transaction - Private | Completed | Clinical Trials - General | ||||
| 4. Later Stage VC (Series C) | 01-Mar-2017 | Completed | Clinical Trials - General | |||
| 3. Early Stage VC (Series B) | 01-Nov-2013 | Completed | Startup | |||
| 2. Early Stage VC (Series A) | 19-Jun-2012 | $5.37M | $12.3M | Completed | Startup | |
| 1. Early Stage VC | 10-Feb-2012 | $6.92M | $6.92M | Completed | Startup |
Ablative Solutions Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series D2 | ||||||||
| Series D1 | ||||||||
| Series C | ||||||||
| Series B | 2,805,392 | $0.001000 | 8% | $5.57 | $8.36 | $5.57 | 4.21% | |
| Series A | 1,287,757 | $0.001000 | 8% | $3.85 | $5.78 | $2.3 | 3.23% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Ablative Solutions Comparisons
Industry
Financing
Details
Ablative Solutions Competitors (12)
One of Ablative Solutions’s 12 competitors is HistoSonics, a Private Equity-Backed company based in Plymouth, MN.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| HistoSonics | Private Equity-Backed | Plymouth, MN | ||||
| Nico (Surgical Devices) | Formerly VC-backed | Indianapolis, IN | ||||
| Sanovas | Formerly VC-backed | Petaluma, CA | ||||
| Symple Surgical | Venture Capital-Backed | Flagstaff, AZ | ||||
| CooperSurgical | Corporate Backed or Acquired | Trumbull, CT |
Ablative Solutions Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Ablative Solutions Patents
Ablative Solutions Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4518938-A2 | Radial compatible catheter for peri-vascular fluid injection | Pending | 06-May-2022 | ||
| EP-4518938-A4 | Radial compatible catheter for peri-vascular fluid injection | Pending | 06-May-2022 | ||
| US-20230355292-A1 | Radial compatible catheter for peri-vascular fluid injection | Pending | 06-May-2022 | ||
| WO-2023215654-A2 | Radial compatible catheter for peri-vascular fluid injection | Inactive | 06-May-2022 | ||
| WO-2023215654-A3 | Radial compatible catheter for peri-vascular fluid injection | Inactive | 06-May-2022 | A61M25/0084 |
Ablative Solutions Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Ablative Solutions Investors (11)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| CKM Capital | Venture Capital | Minority | ||
| Angel (individual) | Minority | |||
| RueOne Investments | Growth/Expansion | Minority | ||
| Dempsey Ventures | Family Office | Minority | ||
| BioStar Capital | Venture Capital | Minority |
Ablative Solutions FAQs
-
When was Ablative Solutions founded?
Ablative Solutions was founded in 2011.
-
Where is Ablative Solutions headquartered?
Ablative Solutions is headquartered in Wakefield, MA.
-
What is the size of Ablative Solutions?
Ablative Solutions has 19 total employees.
-
What industry is Ablative Solutions in?
Ablative Solutions’s primary industry is Surgical Devices.
-
Is Ablative Solutions a private or public company?
Ablative Solutions is a Private company.
-
What is Ablative Solutions’s current revenue?
The current revenue for Ablative Solutions is .
-
How much funding has Ablative Solutions raised over time?
Ablative Solutions has raised $215M.
-
Who are Ablative Solutions’s investors?
CKM Capital, , RueOne Investments, Dempsey Ventures, and BioStar Capital are 5 of 11 investors who have invested in Ablative Solutions.
-
Who are Ablative Solutions’s competitors?
HistoSonics, Nico (Surgical Devices), Sanovas, Symple Surgical, and CooperSurgical are some of the 12 competitors of Ablative Solutions.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
